Max MyHealth Digital Platform & CSR Initiatives slide image

Max MyHealth Digital Platform & CSR Initiatives

MAX Healthcare Network P&L Statement: 9M FY24 Gross revenue¹ Net revenue Direct costs Contribution Indirect overheads Figs in INR Cr FY21 FY22 FY23 9M FY24 Amount % NR Amount % NR Amount % NR Amount % NR 3,881 5,509 6,236 5,325 3,629 100.0% 5,218 100.0% 5,904 100.0% 5,049 100.0% 1,508 41.6% 2,103 40.3% 2,304 39.0% 1,968 39.0% 2,121 58.4% 3,115 59.7% 3,600 61.0% 3,081 61.0% 1,485 40.9% 1,725 33.1% 1,964 33.3% 1,677 33.2% Operating EBITDA¹ ESOP (Equity-settled scheme) Movement in fair value of contingent consideration payable and amortisation of contract assets³ 636 17.5% 1,390 26.6% 1,636 27.7% 1,404 27.8% 27 0.7% 34 0.7% 34 0.6% 36 0.7% 1 0.0% 7 0.1% 4 0.1% 6 0.1% Transaction cost including QIP related cost & Loss on fair valuation of pre-merger holding of Radiant under 249 6.9% Ind AS 103 Exceptional item: Payment to employees under VRS 9 0.2% Reported EBITDA 359 9.9% 1,340 25.7% 1,597 27.1% 1,362 27.0% Finance costs (net) 187 5.2% 112 2.2% 39 0.7% (34) (0.7%) Depreciation and amortisation 216 6.0% 248 4.8% 260 4.4% 200 4.0% Profit/ (Loss) before tax (45) (1.2%) 979 18.8% 1,298 22.0% 1,196 23.7% Tax 50 1.4% 143 2.7% (30) (0.5%) 229 4.5% Profit (Loss) after tax (95) (2.6%) 837 16.0% 1,328 22.5% 966 19.1% Note: The numbers for the previous period have been re-casted and re-grouped to make them comparable with the disclosures in the current period 2. 1. FY22 includes gross revenue of INR 236 Cr and EBITDA of INR 85 Cr from Covid-19 vaccination & related antibody tests compared to INR 2 Cr revenue in FY23 Non-cash item represents the change in fair value of contingent consideration payable to Trust/Society over the balance period (~19 to 30 years) under O&M Contracts and represents change in the WACC, time value of discounted liability and impact of changes in future business plan projections 3. Includes impact of one time reversal of INR 244 Cr deferred tax liability (net of capital gains tax) in FY23 pursuant to voluntary liquidation of a subsidiary 26
View entire presentation